Physician profile
Moises Issa
NPI 1558357780
$16,905.99
in general payments reported to CMS, 2019-2025
56 companies · $4,349 in 2025
The $4,349 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,275 · 2020: $379 · 2021: $1,198 · 2022: $1,501 · 2023: $1,166 · 2024: $3,038 · 2025: $4,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,223 · Travel and Lodging: $2,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,223.41 |
| Travel and Lodging | $2,329.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,769.43 | 2019-2025 | Leqvio |
| Amgen INC. | $2,425.70 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $2,305.74 | 2019-2025 | Aveir, Gallant, Freestyle Libre |
| Lilly USA, LLC | $652.97 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $576.30 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $554.99 | 2021-2025 | |
| Pfizer INC. | $484.75 | 2019-2025 | |
| Novo Nordisk INC | $448.37 | 2019-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $304.12 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Insulet Corporation | $291.40 | 2021-2025 | Omnipod, Omnipod |
| Intra-Sana Laboratories | $208.01 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Hologic Sales and Service, LLC | $207.38 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Janssen Pharmaceuticals, INC | $184.08 | 2021-2024 | Xarelto |
| Amarin Pharma, INC. | $180.77 | 2021-2022 | |
| Dexcom, INC. | $179.83 | 2024 | Dexcom G6 Transmitter |
Show all 53 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moises Issa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.